Impact of the non-small cell lung cancer in Brazil

Authors

  • Cristina Ferreira Pfizer, São Paulo, Brasil.
  • Vivian Blunk Pfizer, São Paulo, Brasil.
  • Carlos Felipe Santana Pfizer, São Paulo, Brasil.
  • Haline Squiassi Pfizer, São Paulo, Brasil.

DOI:

https://doi.org/10.21115/JBES.v8.n2.p91-98

Keywords:

neoplasms, lung, lung neoplasms, health impact assessment

Abstract

Lung cancer is considered the major cause of death due to cancer in Brazil and worldwide. Among the main types of lung cancer, non-small cell lung cancer corresponds to approximately 85% of cases of the disease. The high mortality can be attributed to the late diagnosis once most of the patients are diagnosed when the disease is at an advanced stage. Non-small cell lung cancer management requires an intensive use of cares, besides multidisciplinary approach at diagnoses, treatment and rehabilitation, what in a finite resources set, bring relevant opportunity cost to health system about resource offer in oncologic assistance. Therefore, the aim of this study was to describe the impact that non-small cell lung cancer promotes in Brazilian society, through literature search

Downloads

Download data is not yet available.

Published

2016-08-20

How to Cite

Ferreira, C., Blunk, V., Santana, C. F., & Squiassi, H. (2016). Impact of the non-small cell lung cancer in Brazil. Jornal Brasileiro De Economia Da Saúde, 8(2), 91–98. https://doi.org/10.21115/JBES.v8.n2.p91-98

Issue

Section

Artigos